The pharmacogenetics of analgesia

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 14, 2007, Pages 2235-2245

  Stamer, Ulrike M ^a   Stüber, Frank ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Analgesia; CYP2D6; Cytochrome P450 (CYP); Opioid receptor; Pharmacogenetics; Polymorphism

Indexed keywords

ANALGESIC AGENT; CATECHOL METHYLTRANSFERASE; CELECOXIB; COCODAMOL; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DICLOFENAC; IBUPROFEN; MELANOCORTIN 1 RECEPTOR; MELOXICAM; METOCLOPRAMIDE; MORPHINE; MU OPIATE RECEPTOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE RECEPTOR; OXYCODONE; PARACETAMOL; PHENYTOIN; PIROXICAM; TIMOLOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; WARFARIN;

ANALGESIA; ANALGESIC ACTIVITY; CANCER PAIN; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PAIN; PATIENT CARE; PHARMACOGENETICS; POSTOPERATIVE PAIN; RESPIRATION DEPRESSION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANALGESIA; ANALGESICS; ANIMALS; HUMANS; PAIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 35549000170     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.14.2235     Document Type: Review

References (53)

1. LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998):1200-1205.
2. PHILLIPS KA, VEENSTRA DL, OREN E, LEE JK, SADEE W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 286(18):2270-2279.
3. SPINA E, SCORDO MG: Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging (2002) 19:299-320.
4. DALY AK, BROCKMOLLER J, BROLY F et al.: Nomenclature for human CYP2D6 alleles. Pharmacogenetics ((1996) 6:193-201.
5. MAREZ D, LEGRAND M, SABBAGH N et al.: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics (1997) 7:193-202.
6. SACHSE C, BROCKMOLLER J, BAUER S, ROOTS I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. (1997) 60:284-295.
7. INGELMAN-SUNDBERG M, OSCARSON M, MCLELLAN RA: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. (1999) 20(8):342-349.
8. RAIMUNDO S, TOSCANO C, KLEIN K et al.: A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. (2004) 76(2):128-138.
9. STAMER UM, MUSSHOFF F, KOBILAY M, MADEA B, HOEFT A, STÜBER F: Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. (2007) [Epub ahead of print].
10. POULSEN L, BROSEN K, ARENDT-NIELSEN L, GRAM LF, ELBAEK K, SINDRUP SH: Codeine and morphine in extensive and poor metabolisers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. (1996) 51:289-295.
11. ECKHARDT K, LI S, AMMON S, SCHANZLE G, MIKUS G, EICHELBAUM M: Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain (1998) 76:27-33.
12. WILLIAMS DG, HATCH DJ, HOWARD RF: Codeine phosphate in paediatric medicine. Br. J. Anaesth. (2001) 86:413-421.
13. WILLIAMS DG, PATELA, HOWARD RF: Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br. J. Anaesth. (2002) 89:839-845.
14. FAGERLUND TH, BRAATEN O: No pain relief from codeine? An introduction to pharmacogenomics. Acta Anaesthesiol. Scand. (2001) 68:140-149.
15. GASCHE Y, DAALI Y, FATHI M et al.: Codeine intoxication associated with ultrarapid CY52D6 metabolism. N. Engl. J. Med. (2004) 351 (27):2827-2831.
16. KIRCHHEINER J, SCHMIDT H, TZVETKOV M et al.: Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolisers due to CYP2D6 duplication. Pharmacogenom. J. (2006) 7(4):257-265.
17. RAFFA RB, FRIDERICHS E, REIMANN W et al.: Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J. Pharmacol. Exp. Ther. (1993) 267:331-340.
18. POULSEN L, ARENDT-NIELSEN L, BROSEN K, SINDRUP SH: The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. (1996) 60:636-644.
19. STAMER UM, LEHNEN K, HÖTHKER F et al.: Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain (2003) 105:231-238.
20. WANG G, ZHANG H, HE F. FANG X: Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur. J. Clin. Pharmacol. (2006) 62(11):927-931.
21. EAP CB, BROLY F, MINO A et al.: Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J. Clin. Psychopharmacol. (2001) 21:229-234.
22. SHIRAN MR, CHOWDRY J, ROSTAMI-HODJEGAN A et al.: A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br. J. Clin. Pharmacol. (2003) 56:220-224.
23. IRIBARNE C, BERTHOU F, BAIRD S et al.: Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. (1996) 9:365-373.
24. PICK CG, CHENG J, PAUL D, PASTERNAK GW: Genetic influences in opioid analgesic sensitivity in mice. Brain Res. (1991) 556:295-298.
25. MOGIL JS, WILSON SG, BON K et al.: Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain (1999) 80:67-82.
26. KIRCHHEINER J, STÖRMER E, MEISEL C, STEINBACH N, ROOTS I, BROCKMOLLER J: Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabotites. Pharmacogenetics (2003) 13(8):473-480.
27. TANG C, SHOU M, RUSHMORE TH et al.: In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in vivo pharmacokinetics. Pharmacogenetics (2001) 11:223-235.
28. KIRCHHEINER J, MEINEKE I, FREYTAG G, MEISEL C, ROOTS I, BROCKMOLLER J: Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin. Pharmacol. Ther. (2002) 72(1):62-75.
29. KIRCHHEINER J, SASSE J, MEINEKE I, ROOTS I, BROCKMOLLER J: Trimipramine pharmacogenetics after intravenous and oral administration in cariiers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics (2004) 13(12):721-728.
30. KIRCHHEINER J, NICKCHEN K, BAUER M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry (2004) 9(5):442-473.
31. KOCH T, KROSLAK T, AVERBECK M et al.: Allelic variation S268P of the human μ-opioid receptor affects both desensitization and G protein coupling. Mol. Pharmacol. (2000) 58:328-334.
32. BEFORT K, FILLIOL D, DECAILLOT FM, GAVERIAUX-RUFF C, HOEHE MR, KIEFFER BL: A single nucleotide polymorphic mutation in the human μ-opioid receptor severely impairs receptor signalling. J. Biol. Chem. (2001) 276:3130-3137.
33. L TSCH J, SKARKE C, GROSCH S, DARIMONT J, SCHMIDT H, GEISSLINGER G: The polymorphism A118G of the human μ-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics (2002) 12:3-9.
34. LÖTSCH J, ZIMMERMANN M, DARIMONT J et al.: Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology (2002) 97:814-819.
35. KLEPSTAD P, RAKVAG TT, KAASA S et al.: The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. (2004) 48:1232-1239.
36. CHOU WY, YANG LC, LU HF et al.: Association of μ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. (2006) 50(7):787-792.
37. CHOU WY, WANG CH, LIU PH, LIU CC, TSENG CC, JAWAN B: Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology (2006) 105(2):334-337.
38. LANDAU R: One size does not fit all: genetic variability of μ-opioid receptor and postoperative morphine consumption. Anesthesiology (2006) 105(2):235-237.
39. BELFER I, WU T, KINGMAN A, KRISHNARAJU RK, GOLDMAN D, MAX MB: Candidate gene studies of human pain mechanisms. Anesthesiology (2004) 100:1562-1572.
40. EISENACH JC: Fishing for genes: Practical ways to study polymorphisms for pain. Anesthesiology (2004) 100:1343-1344.
41. MAX MB: Assessing pain candidate gene studies. Pain (2004) 109:1-3.
42. GEAR RW, MIASKOWSKI C, GORDON NC, PAUL SM, HELLER PH, LEVINE JD: κ-opioids produce significantly greater analgesia in women than in men. Nat. Med. (1996) 2:1248-1250.
43. GEAR RW, MIASKOWSKI C, GORDON NC, PAUL SM, HELLER PH, LEVINE JD: The κ opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain (1999) 83:339-345.
44. MOGIL JS, WILSON SG, CHESLER EJ et al.: The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc. Natl. Acad. Sci. USA (2003) 100(8):4867-4872.
45. MOGIL JS, RITCHIE J, SMITH SB et al.: Melanocortin-1 receptor gene variants affect pain and μ-opioid analgesia in mice and humans. J. Med. Genet. (2005) 42(7):583-587.
46. LIEM EB, LIN CM, SULEMAN MI et al.: Anesthetic requirement is increased in redheads. Anesthesiology (2004) 101:279-283.
47. LIEM EB, JOINER TV, TSUEDA K, SESSLER DI: Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads. Anesthesiology (2005) 102:509-514.
48. ZUBIETA JK, HEITZEG MM, SMITH YR et al.: Val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science (2003) 299(5610):1240-1243.
49. RAKVAG TT, KLEPSTAD P, BAAR C et al: The Val158 Met polymorphism of the human catechol O-methyltransferase (COMT) gene may influence morphine requirements in cancer patients. Pain (2005) 116:73-78.
50. REYES-GIBBY CC, SHETE S, RAKVAG T et al.: Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain (2006) 130(1-2):25-30.
51. KIM H, LEE H, ROWAN J, BRAHIM J, DIONNE RA: Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol. Pain (2006) 2:24.
52. WERNER U, WERNER D, RAU T, FROMM ME HINZ B, BRUNE K: Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin. Pharmacol. Ther. (2003) 74(2):130-137,
53. WERNER D, WUTTKE H, FROMM MF et al.: Effect of amiodarone on the plasma levels of metoprolol. Am. J. Cardiol. (2004) 94(10):1319-1321.